This phase Ib trial tests the safety, side effects, and best dose of the combination of vismodegib and atezolizumab in treating patients with non-small cell lung cancer (NSCLC) that has come back after a period of improvement (recurrent) or has spread from where it first started (primary site) to other places in the body (metastatic). Vismodegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving a combination of vismodegib and atezolizumab may be safe, tolerable and/or effective than either drug alone in treating patients with recurrent or metastatic NSCLC.

Start Date31 Dec 2024

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

[+1]

NCT06344052

/ RecruitingPhase 2

A Phase 2 Study to Assess the Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an add-on to hedgehog pathway inhibitor therapy.
Researchers will compare the objective response rate for treated Basal cell carcinoma tumors between 3 treatment Arms.
* Arm 1 participants will receive daily hedgehog pathway inhibitor, and 3 cycles of SP-002 treatment.
* Arm 2 participants will receive daily hedgehog pathway inhibitor, and 1 cycle of SP-002 treatment.
* Arm 3 participants will receive daily hedgehog pathway inhibitor only.

Start Date09 Apr 2024

Sponsor / Collaborator

Stamford Pharmaceuticals, Inc.

NCT05561634

/ Not yet recruitingPhase 2IIT

Evaluation of Radiotherapy After Complete Response to Sonic Hedgehog Pathway Inhibitors in Patients With Locally Advanced Basal Cell Carcinoma: a Prospective Multicenter Study

Locally advanced basal cell carcinoma (BCC) are large BCCs or BCCs located in areas subject to functional and aesthetic risk following surgery or radiotherapy. In these particular situations, surgery and radiotherapy are sometimes not appropriate, and Sonic Hedgehog inhibitors (SHHi) (Vismodegib and Sonidegib) can be proposed. SHHi are effective treatments in laBCC but most CR patients discontinue treatment because of tolerability. Approximately 65% of the population experience a relapse after discontinuation. A few cases of patients treated concomitantly by radiotherapy and vismodegib have been reported in the literature, suggesting that combining vismodegib and concomitant radiotherapy results in an improved overall response compared to a single modality treatment. There is no study evaluating a "consolidation radiotherapy" after complete response to SHHi. We carry out a prospective multicenter study in order to evaluate consolidation radiotherapy in patients with laBCC after achieving complete response with SHHi, with the hypothesis of reducing recurrence after discontinuation of SHHi.

Start Date01 Jul 2023

Sponsor / Collaborator

Centre Hospitalier Universitaire de Lille

[+1]

100 Clinical Results associated with Vismodegib

100 Translational Medicine associated with Vismodegib

100 Patents (Medical) associated with Vismodegib

1,409

Literatures (Medical) associated with Vismodegib

01 Apr 2025·American Journal of Physiology-Gastrointestinal and Liver Physiology

Inhibition of hedgehog signaling ameliorates severity of chronic pancreatitis in experimental mouse models

Article

Author: Tarique, Mohammad ; Guan, JiaShiung ; Bava, Ejas P. ; Sahay, Preeti ; Iyer, Srikanth ; Dudeja, Vikas ; Crossman, David K. ; Giri, Sagnik ; Vaish, Utpreksha ; Jain, Tejeshwar ; Jin, Xiuwen ; Moon, Sabrina

Hedgehog signaling is activated in human and experimental models of CP. Inhibition of hedgehog signaling using an FDA-approved inhibitor, vismodegib, leads to the resolution of fibrosis and improves CP. This study has immense and immediate translational benefits.

01 Apr 2025·American Journal of Surgical Pathology

Clinicopathologic and Molecular Characterization of Basal Cell Carcinoma Arising at Sun-protected Sites

Article

Author: Draper, Elizabeth ; Li, Yvonne Y. ; Hanna, John ; Mahadevan, Navin R. ; Russell-Goldman, Eleanor ; Laga, Alvaro C.

Basal cell carcinomas (BCC) are driven primarily by cumulative ultraviolet (UV) radiation exposure resulting in activation of the Hedgehog (Hh) signaling pathway, often as a result of UV-mediated Patched-1 (PTCH1) gene inactivation. Accordingly, BCCs most commonly arise at sun-exposed sites such as the head and neck. Very rarely, BCCs can arise at sun-protected sites such as the genital skin and perianal area. This can pose significant diagnostic challenges not only due to the rarity of BCC at these sites but also due to the potential morphologic overlap with other entities such as basaloid squamous cell carcinoma, trichoblastic carcinoma, and even benign neoplasms such as trichoblastomas. Hh pathway alterations have not yet been described in BCCs arising at genital and perianal sites, and the role of UV radiation is uncertain at these anatomic locations. To address this ambiguity, we report the clinicopathologic features of a cohort of 14 BCCs arising at sun-protected sites (perianal n=7, vulva n=4, scrotum n=3). Furthermore, we use a next-generation DNA sequencing platform to investigate their pathogenesis and compare it to that of a cohort of 8 BCCs arising on sun-exposed skin. We find that BCCs arising on sun-protected sites display a spectrum of morphologic patterns, rarely recur, and do not metastasize. Both sun-protected and sun-exposed BCCs are characterized by recurrent PTCH1 alterations (93% and 100% of cases, respectively), supporting the classification of the tumors arising at sun-protected sites as bona fide BCCs. Notably, in contrast to conventional BCCs, none of the sun-protected BCCs harbored a UV mutation signature, suggesting an alternative mechanism of mutagenesis. Furthermore, the presence of upstream Hh pathway alterations in sun-protected BCCs supports their susceptibility to Hh pathway inhibitors such as vismodegib and sonidegib.

24 Mar 2025·Journal of Biomolecular Structure and Dynamics

Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development

Article

Author: Afreen, Shagufta ; Mitra, Debanjan ; Abdalla, Mohnad ; Das Mohapatra, Pradeep K.

The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.Communicated by Ramaswamy H. Sarma.

News (Medical) associated with Vismodegib

17 Jan 2025

·stamfordpharmaceuticals.com

Stamford announces positive results from Phase 2 Study of SP-002 in combination with 4-weeks of vismodegib in multi-lesional Basal Cell Carcinoma patients

January 17, 2025 Stamford has announced positive results for its ASN-002-003 multi-lesional clinical trial (NCT 04416516. Protocol No ASN-002-003) evaluating SP-002, an Adenovirus-5 replication deficient vector encoding human Interferon- in combination with vismodegib (a Hedgehog Pathway Inhibitor) in subjects presenting with multiple BCCs. “We are very pleased with these positive results from the Phase 2 study demonstrating the safety and efficacy of our gene therapy for patients with multiple nodular and superficial BCCs. We are particularly excited that the histopathologic criteria, which would allow responsive patients to be identified at screening and used for patient selection. This histopathologic criterion was first noted in the ASN-002-001 clinical study and has now been successfully reproduced in ASN-002-003. We believe this enables us to develop a useful treatment option for patients with nodular BCC and addresses the important need for a non-surgical option for those with BCCs in the H-zone or for those who are not ideal candidates for surgery.” Dr Clement Leong (PhD), CEO of Stamford Pharmaceuticals Press Release: Stamford announces positive results from Phase 2 Study of SP-002 in combination with 4-weeks of vismodegib in multi-lesional Basal Cell Carcinoma patients

Phase 2Gene TherapyClinical Result

10 Dec 2024

·www.prnewswire.com

Curis Announces Additional Data from TakeAim Leukemia Study

LEXINGTON, Mass., Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting. The additional data presented include data for 21 patients with a FLT3 mutation (FLT3m) who had received fewer than 3 lines of prior therapy and were treated with emavusertib as monotherapy at the Recommended Phase 2 Dose (RP2D) of 300 mg BID. This brings the total number of patients dosed at the RP2D from 12 to 21 patients. Data show 10 objective responses in 19 response-evaluable patients: 6 complete remission (CR), 2 CR with either a complete remission with incomplete hematological recovery (CRi) or a partial hematological recovery (CRh) and 2 morphologic leukemia-free state (MLFS). Prior therapies of responders included Venetoclax (5/10), HMA (6/10), and FLT3i (6/10). Two of the 21 patients were treated, but discontinued treatment prior to first disease assessment (death occurred at Day 8 and Day 13, respectively), and were not included as response-evaluable patients. Two patients who achieved a CR and CRi, respectively, proceeded to allogenic stem cell transplantation. Responses were achieved rapidly in this population, with 7 of 10 responses reported at the first assessment (Cycle 2 Day 1). "We continue to be pleased with the monotherapy data in R/R AML patients with a FLT3 mutation," said James Dentzer, President and CEO of Curis, "and believe these data further support the exciting potential of emavusertib's novel mechanism to address a significant unmet need in patients with AML." About Curis, Inc. Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at . Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding additional data from the TakeAim Leukemia study and the therapeutic potential of emavusertib in patients with AML; statements concerning research, development, clinical trials and commercialization plans, timelines, anticipated results or the therapeutic potential of emavusertib including the progression, expansion, use, safety, efficacy, rates and duration of responses, mutations or potential biomarkers, and potential benefits of emavusertib in clinical trials as a monotherapy and/or as a combination therapy; and statements of assumptions underlying any of the foregoing. Forward-looking statements may contain the words "believes," "expects," "anticipates," "plans," "intends," "seeks," "estimates," "assumes," "predicts," "projects," "targets," "will," "may," "would," "could," "should," "continue," "potential," "focus," "strategy," "mission," or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. Curis may experience adverse results, delays and/or failures in its drug development programs and may not be able to successfully advance the development of its drug candidates in the time frames it projects, if at all. Curis's drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization. Favorable results seen in preclinical studies and early clinical trials of Curis's drug candidates may not be replicated in later trials. Curis is dependent on the success of emavusertib and any delays in the development of emavusertib could have a material adverse effect on its business. There can be no guarantee that the collaboration agreement with Aurigene will continue for its full term, or the CRADA with NCI, that Curis or its collaborators will each maintain the financial and other resources necessary to continue financing its portion of the research, development and commercialization costs, or that the parties will successfully discover, develop or commercialize drug candidates under the collaboration. Regulatory authorities may determine to delay or restrict Genentech's and/or Roche's ability to continue to commercialize Erivedge in basal cell carcinoma. Competing drugs may be developed that are superior to Erivedge. In connection with its agreement with Oberland Capital, Curis faces risks relating to the transfer and encumbrance of certain royalty and royalty-related payments on commercial sales of Erivedge, including the risk that, in the event of a default by Curis or its wholly-owned subsidiary, Curis could lose all retained rights to future royalty and royalty-related payments, Curis could be required to repurchase such future royalty and royalty-related payments at a price that is a multiple of the payments it has received, and its ability to enter into future arrangements may be inhibited, all of which could have a material adverse effect on its business, financial condition and stock price. Curis will require substantial additional capital to fund its business. Based on its available cash resources, it does not have sufficient cash on hand to support current operations within the next 12 months from the date of this press release. If it is not able to obtain sufficient funding, it will be forced to delay, reduce in scope or eliminate the development emavusertib, including related clinical trials and operating expenses, potentially delaying the time to market for, or preventing the marketing of, emavusertib, which could adversely affect its business prospects and its ability to continue operations, and would have a negative impact on its financial condition and its ability to pursue its business strategies. Curis faces substantial competition. Curis and its collaborators face the risk of potential adverse decisions made by the FDA and other regulatory authorities, investigational review boards, and publication review bodies. Curis may not obtain or maintain necessary patent protection and could become involved in expensive and time-consuming patent litigation and interference proceedings. Unstable market and economic conditions, natural disasters, public health crises, political crises and other events outside of Curis's control could significantly disrupt its operations or the operations of third parties on which Curis depends and could adversely impact Curis's operating results and its ability to raise capital. Other important factors that may cause or contribute to actual results being materially different from those indicated by forward-looking statements include the factors set forth under the captions "Risk Factor Summary" and "Risk Factors" in our most recent Form 10-K and Form 10-Q, and the factors that are discussed in other filings that we periodically make with the Securities and Exchange Commission. In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as representing Curis's views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by law. SOURCE Curis, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Orphan DrugLicense out/inPhase 2ASCOClinical Result

07 Nov 2024

·www.prnewswire.com

Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

LEXINGTON, Mass., Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here from the investor section of the Curis website. A replay of the conference call will be available at . About Curis, Inc. Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS) with either a FLT3 mutation or a splicing factor mutation (U2AF1 or SF3B2), and as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML and MDS. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at . SOURCE Curis, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/inOrphan DrugFinancial StatementPhase 1

100 Deals associated with Vismodegib

External Link

KEGG	Wiki	ATC	Drug Bank
D09992	Vismodegib	L01XX43	DB08828

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Metastatic basal cell carcinoma	European Union	Roche Registration GmbH	12 Jul 2013
Metastatic basal cell carcinoma	Iceland	Roche Registration GmbH	12 Jul 2013
Metastatic basal cell carcinoma	Liechtenstein	Roche Registration GmbH	12 Jul 2013
Metastatic basal cell carcinoma	Norway	Roche Registration GmbH	12 Jul 2013
Basal Cell Carcinoma	United States	Genentech, Inc.	30 Jan 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic basal cell carcinoma	Preclinical	Australia	Hoffmann-La Roche Ltd.	01 Jul 2011
Metastatic basal cell carcinoma	Preclinical	Russia	Hoffmann-La Roche Ltd.	01 Jul 2011
Metastatic basal cell carcinoma	Preclinical	Argentina	Hoffmann-La Roche Ltd.	01 Jul 2011
Metastatic basal cell carcinoma	Preclinical	New Zealand	Hoffmann-La Roche Ltd.	01 Jul 2011
Pancreatic Ductal Adenocarcinoma	Preclinical	United Kingdom	Roche Pharma AG	01 Feb 2011
Pancreatic Ductal Adenocarcinoma	Preclinical	United Kingdom	Genentech, Inc.	01 Feb 2011
Metastatic Pancreatic Cancer	Preclinical	United States	Genentech, Inc.	17 Sep 2010
Basal Cell Nevus Syndrome	Preclinical	United States	Genentech, Inc.	01 Aug 2009
Ovarian Cancer	Preclinical	-	Genentech, Inc.	01 Dec 2008
Metastatic Colorectal Carcinoma	Preclinical	-	Genentech, Inc.	01 May 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02091141 (MyPathway, CTgov)	Phase 2	Advanced Malignant Solid Neoplasm \| Bladder Cancer \| Biliary Tract Neoplasms \| Salivary Gland Neoplasms	673	Trastuzumab+Pertuzumab (Trastuzumab Plus Pertuzumab)	gaibufpfqi(dlntzjtffz) = rzlutnsjwq xieeckvffj (fmktmzoabv, pkfdtqbxsd - bowcpssgvg) View more	-	23 Jul 2024
NCT02091141 (MyPathway, CTgov)	Phase 2		673	atezolizumab (Atezolizumab)	gaibufpfqi(dlntzjtffz) = kemsiqdhvv xieeckvffj (fmktmzoabv, cphmqxbsus - qkhjuvpriz) View more	-	23 Jul 2024
ENV-101 (EADV2023)	Phase 2	Basal Cell Carcinoma PTCH1 Loss of Function mutations	44	Taladegib 200 mg	qmskylynqu(csocyvgswd) = Patient reported alopecia during the study hbaiaqloqj (vahqneaukk ) View more	Positive	11 Oct 2023
ENV-101 (EADV2023)	Phase 2	Basal Cell Carcinoma PTCH1 Loss of Function mutations	44	Vismodegib		Positive	11 Oct 2023
WCD2023	Not Applicable	Xeroderma Pigmentosum	-	Vismodegib 150 mg/day	osvtypfinx(enpfilmtbu) = hezwhpydlw jamkscchqh (qkatmgddrq )	-	03 Jul 2023
EAN2023	Not Applicable	SHH-activated	1	Vismodegib 150 mg	qemnwiqqxo(rvlwyjivzy) = The treatment was well tolerated, except for increased creatine phosphokinase (CTCAE v3.0 grade 1) fnmabcqphb (hmwdwatuip ) View more	Positive	28 Jun 2023
NCT02465060 (EAY131, ASCO2022) Manual	Phase 2	Neoplasms PTCH1 Mutation \| SMO Mutation	31	vismodegib 150 mg (all analyzable pts)	(vjqppofgle) = iporejxnmd kcpattqrtp (ggxlmtrahq ) View more	Negative	02 Jun 2022
NCT02465060 (EAY131, ASCO2022) Manual	Phase 2	Neoplasms PTCH1 Mutation \| SMO Mutation	31	vismodegib 150 mg (MATCH-confirmed)	(vjqppofgle) = dzrnlxzfne kcpattqrtp (ggxlmtrahq ) View more	Negative	02 Jun 2022
NCT02436408 (VISORB \| VISORB trial, CTgov)	Phase 4	Basal Cell Carcinoma	35	Vismodegib	mphsahprjp(xlsakpbyid) = uccbonsfat ezteqogytl (ifjtnlfcpl, dptjitprus - gdrjxvzthj) View more	-	28 Oct 2021
ASN2021	Not Applicable	-	-	Vismodegib	rjphyinlpw(fxuihoozql) = iscuifytca rplfpkndhg (veqsqdokth )	Positive	27 Oct 2021
NCT02337517 (CTgov)	Phase 2	Steroid Refractory Graft Versus Host Disease \| Chronic graft-versus-host disease	6	Laboratory Biomarker Analysis+Vismodegib	ofbluboeuu(hrgigulslw) = hrapzesrnk uxkoafvlub (dktnlrggsf, pnddltxvlg - pbelymlkjv) View more	-	16 Jun 2021
NCT02667574 (VISMONEO, Pubmed) Manual	Phase 2	Basal Cell Carcinoma Neoadjuvant	55	Vismodegib	(kshvgxkofz) = ubfycahsfw qjdftfifgi (ckvntqskcy, 67 - 90) View more	Positive	26 Apr 2021
NCT00957229 (GDC-0449, CTgov)	Phase 2	Basal Cell Nevus Syndrome	41	GDC-0449 (Sugar Pill)	aocflmofzu(ntqgkwoenw) = wlqsecjqto awbhddzrsz (knxupjtdzs, fjblaumyzq - whtmuxnhfo) View more	-	11 Jan 2021
NCT00957229 (GDC-0449, CTgov)	Phase 2	Basal Cell Nevus Syndrome	41	GDC-0449 (GDC-0449)	aocflmofzu(ntqgkwoenw) = fghsmizxpp awbhddzrsz (knxupjtdzs, bpklvwzaap - deuowkcjlr) View more	-	11 Jan 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis